Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus
Identifieur interne : 001392 ( Main/Exploration ); précédent : 001391; suivant : 001393Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus
Auteurs : N. Ezra [États-Unis] ; J. Jorizzo [États-Unis]Source :
- Clinical and Experimental Dermatology [ 0307-6938 ] ; 2012-06.
English descriptors
- Teeft :
- Antimalarial, Antimalarial medications, Antimalarial response rate, Antimalarial therapy, Antimalarial treatment, Arthritis rheum, Autoimmune, Autoimmune disease, British association, Chloroquine, Cigarette smoke, Cigarette smoking, Clin, Clinical score, Cohort, Current smoking, Cutaneous, Cutaneous lupus erythematosus, Dermatol, Dermatologist, Dermatology, Discoid lupus erythematosus, Disease activity, Erythematosus, Experimental dermatology, Hydroxychloroquine, Hydroxychloroquine sulfate, Irreversible loss, Jorizzo, Lupus, Lupus erythematosus, Lupus erythematosus tumidus, Medication, Medication adherence, Myocardial infarction, Nonadherence, Nonsmoker, Predictor, Quinacrine, Rheum, Scle, Smoker, Smoking, Subacute cutaneous lupus erythematosus, Systemic, Systemic lupus erythematosus, Therapeutic agents.
Abstract
Antimalarials, such as chloroquine and hydroxychloroquine, have been used to treat cutaneous and systemic lupus erythematosus for decades with excellent therapeutic efficacy. Smoking seems to inhibit the therapeutic efficacy of antimalarials when treating cutaneous lupus erythematosus (CLE), but the reason behind this observation is unclear. In addition, antimalarials have been associated with several potentially serious adverse effects, including irreversible loss of vision. The aim of this literature review is to discuss the evidence for how cigarette smoking interferes with antimalarial efficacy in the treatment of CLE. Evidence‐based data with long‐term follow‐up will allow determination of the aetiology for diminished antimalarial response, and enable selection of the best treatment to maximize long‐term remission in CLE.
Click here for the corresponding questions to this CME article.
Url:
DOI: 10.1111/j.1365-2230.2011.04266.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000029
- to stream Istex, to step Curation: 000029
- to stream Istex, to step Checkpoint: 000401
- to stream Main, to step Merge: 001393
- to stream Main, to step Curation: 001392
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus</title><author><name sortKey="Ezra, N" sort="Ezra, N" uniqKey="Ezra N" first="N." last="Ezra">N. Ezra</name></author><author><name sortKey="Jorizzo, J" sort="Jorizzo, J" uniqKey="Jorizzo J" first="J." last="Jorizzo">J. Jorizzo</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:62EA61F47A53C492F530C9309E04566E3B115EEF</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1111/j.1365-2230.2011.04266.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-RMX95VFF-C/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000029</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000029</idno><idno type="wicri:Area/Istex/Curation">000029</idno><idno type="wicri:Area/Istex/Checkpoint">000401</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000401</idno><idno type="wicri:doubleKey">0307-6938:2012:Ezra N:hydroxychloroquine:and:smoking</idno><idno type="wicri:Area/Main/Merge">001393</idno><idno type="wicri:Area/Main/Curation">001392</idno><idno type="wicri:Area/Main/Exploration">001392</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus</title><author><name sortKey="Ezra, N" sort="Ezra, N" uniqKey="Ezra N" first="N." last="Ezra">N. Ezra</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Dermatology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Jorizzo, J" sort="Jorizzo, J" uniqKey="Jorizzo J" first="J." last="Jorizzo">J. Jorizzo</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Dermatology, Center for Dermatology Research, Wake Forest University School of Medicine, Winston‐Salem, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Clinical and Experimental Dermatology</title><title level="j" type="alt">CLINICAL EXPERIMENTAL DERMATOLOGY</title><idno type="ISSN">0307-6938</idno><idno type="eISSN">1365-2230</idno><imprint><biblScope unit="vol">37</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="327">327</biblScope><biblScope unit="page" to="334">334</biblScope><biblScope unit="page-count">8</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2012-06">2012-06</date></imprint><idno type="ISSN">0307-6938</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0307-6938</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Antimalarial</term><term>Antimalarial medications</term><term>Antimalarial response rate</term><term>Antimalarial therapy</term><term>Antimalarial treatment</term><term>Arthritis rheum</term><term>Autoimmune</term><term>Autoimmune disease</term><term>British association</term><term>Chloroquine</term><term>Cigarette smoke</term><term>Cigarette smoking</term><term>Clin</term><term>Clinical score</term><term>Cohort</term><term>Current smoking</term><term>Cutaneous</term><term>Cutaneous lupus erythematosus</term><term>Dermatol</term><term>Dermatologist</term><term>Dermatology</term><term>Discoid lupus erythematosus</term><term>Disease activity</term><term>Erythematosus</term><term>Experimental dermatology</term><term>Hydroxychloroquine</term><term>Hydroxychloroquine sulfate</term><term>Irreversible loss</term><term>Jorizzo</term><term>Lupus</term><term>Lupus erythematosus</term><term>Lupus erythematosus tumidus</term><term>Medication</term><term>Medication adherence</term><term>Myocardial infarction</term><term>Nonadherence</term><term>Nonsmoker</term><term>Predictor</term><term>Quinacrine</term><term>Rheum</term><term>Scle</term><term>Smoker</term><term>Smoking</term><term>Subacute cutaneous lupus erythematosus</term><term>Systemic</term><term>Systemic lupus erythematosus</term><term>Therapeutic agents</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Antimalarials, such as chloroquine and hydroxychloroquine, have been used to treat cutaneous and systemic lupus erythematosus for decades with excellent therapeutic efficacy. Smoking seems to inhibit the therapeutic efficacy of antimalarials when treating cutaneous lupus erythematosus (CLE), but the reason behind this observation is unclear. In addition, antimalarials have been associated with several potentially serious adverse effects, including irreversible loss of vision. The aim of this literature review is to discuss the evidence for how cigarette smoking interferes with antimalarial efficacy in the treatment of CLE. Evidence‐based data with long‐term follow‐up will allow determination of the aetiology for diminished antimalarial response, and enable selection of the best treatment to maximize long‐term remission in CLE.</div><div type="abstract">Click here for the corresponding questions to this CME article.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li><li>Caroline du Nord</li></region></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Ezra, N" sort="Ezra, N" uniqKey="Ezra N" first="N." last="Ezra">N. Ezra</name></region><name sortKey="Jorizzo, J" sort="Jorizzo, J" uniqKey="Jorizzo J" first="J." last="Jorizzo">J. Jorizzo</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001392 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001392 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:62EA61F47A53C492F530C9309E04566E3B115EEF
|texte= Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus
}}
| This area was generated with Dilib version V0.6.33. |  |